NCI Considers ‘Decentralization’ Of Group C To Provide Wider Access, Local Flexibility
In Brief: Broder Invokes Cancer Act Provision To Inform Hammer, Bush Of Potential Damage Of 32% Cut
Lasagna Committee Report Advocates Faster Drug approval, Insurance Coverage For Investigational Drugs, Ancillary Costs
Don’t Blame FDA For All Problems, Broder Says
Outside Experts Might Lengthen NDA Approval, Peck Asserts
Freement Lists Steps For Dealing With Disadvantaged
Trending Stories
- CBER Director Vinay Prasad sidelined staff to jettison Moderna’s mRNA flu shot
- The FY26 funding package gave NCI a raise, but the institute’s buying power is 18% less than it was two decades ago
Lowy: “We still have percentiles, but we’re not allowed to make awards exclusively on the basis of payline.” - Lou Weisbach tells us about his plan to raise $750 billion for the American Center for Cures
- Team USA’s Julie Letai competes in Milan Olympics speed skating event
- Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”
- Mail-out colorectal cancer screening programs extend, rather than replace, clinical care









